This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution strengths ...

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand ...

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes.

Thirteen drugs for cancer and diabetes have been added to the list of essential medicines exempted from value-added tax or VAT, according to the Food and Drug Administration (FDA). Cancer drugs ...

The results were published in The New England Journal of Medicine as part of the OASIS 4 phase 3 trial. The findings show ...

Novo Nordisk India and Emcure Pharma are partnering to introduce Poviztra, a weight-loss medication based on semaglutide, in India. This collaboration aims to enhance accessibility and distribution of ...

Under the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of ...

() -​Novo ‌Nordisk has partnered ‌with India's Emcure Pharmaceuticals ⁠to ‌exclusively distribute and ‍market weight-loss ...

Scientists say they’ve come up with a way for the body to produce its own store of glucagon-like peptide-1 (GLP-1). GLP-1 is ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded ...

Metsera's lead pipeline asset is MET-097i, a GLP-1 receptor agonist designed for once-monthly injection. Novo's weight-loss drugs Wegovy and Eli Lilly's Zepbound and Mounjaro require weekly injections ...